Glibenclamide PCD Pharma Franchise Company
Cafoli Lifecare offers a Glibenclamide PCD pharma franchise built on 6 tablet formulations, including metformin combinations, all manufactured at WHO-GMP certified facilities. This gives franchise partners a well-established oral antidiabetic line for diabetologists and physicians.
What is Glibenclamide?
Glibenclamide (glyburide) is a second-generation sulfonylurea antidiabetic. It lowers blood glucose by stimulating insulin release from pancreatic beta cells through closure of ATP-sensitive potassium channels. Read its profile on MedlinePlus.
Therapeutic Applications
Glibenclamide is prescribed for type 2 diabetes mellitus to improve glycaemic control, most often as an add-on to metformin when diet, exercise and metformin alone are insufficient. Fixed-dose glibenclamide-metformin tablets are widely used. Prescriptions come mainly from diabetologists, endocrinologists and general physicians.
Why Glibenclamide is a High-Potential Molecule for Distributors
Type 2 diabetes is a mass-scale, lifelong condition in India, and sulfonylureas remain a low-cost, widely prescribed second-line therapy — especially the affordable glibenclamide-metformin fixed-dose combinations favoured in high-volume general practice. Continuous, years-long therapy means dependable monthly repeat sales. That large, chronic patient base makes it a steady, high-turnover antidiabetic molecule for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- MedlinePlus: Glibenclamide (Glyburide)
- PubChem: Glibenclamide
Our formulations of Glibenclamide find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: